Kullo Ifirkhar J, Li Guo, Bielak Lawrence F, Bailey Kent R, Sheedy Patrick F, Peyser Patricia A, Turner Stephen T, Kardia Sharon L R
Division of Cardiovascular Diseases, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA.
Mayo Clin Proc. 2006 Feb;81(2):177-82. doi: 10.4065/81.2.177.
To Investigate the association of plasma homocystelne with coronary artery calcification (CAC) in strata based on 10-year risk of coronary heart disease (CHD) in a cohort enriched in persons with hypertension.
Fasting plasma homocystelne was measured by liquid chromatography electrospray tandem mass spectrometry. Coronary artery calcification was measured noninvasively by electron beam computed tomography and CAC score calculated using the method of Agatston et al. The 10-year CHD risk was calculated based on the Framingham risk score. The association of homocysteine with log-transformed CAC score was assessed in the pooled sample and within each risk stratum by linear regression after adjustment for conventional risk factors.
In the 1071 participants studied, homocysteine was associated with CAC quantity (P = .01) after adjustment for CHD risk factors (age, male sex, total and high-density lipoproteln cholesterol, diabetes, history of smoking, body mass Index, and systolic blood pressure), serum creatinine, and statin and hypertension medication use. When the association was assessed in strata based on 10-year CHD risk, homocysteine was significantly (P = .003) associated with CAC quantity in participants at Intermediate 10-year risk of CHD (6%-20%) independent of other risk factors but not in those at lower risk or higher risk.
Plasma homocysteine is associated with quantity of CAC Independent of CHD risk factors. When studied in categories of 10-year CHD risk, the association was significant in participants at intermediate risk but not in those at low or high risk. Plasma homocysteine levels may have clinical utility as a marker of CHD risk in such individuals.
在一个富含高血压患者的队列中,根据冠心病(CHD)10年发病风险分层,研究血浆同型半胱氨酸与冠状动脉钙化(CAC)之间的关联。
采用液相色谱电喷雾串联质谱法测定空腹血浆同型半胱氨酸。通过电子束计算机断层扫描对冠状动脉钙化进行无创测量,并使用阿加斯顿等人的方法计算CAC积分。基于弗雷明汉风险评分计算10年CHD发病风险。在对传统风险因素进行校正后,通过线性回归在汇总样本以及每个风险分层内评估同型半胱氨酸与经对数转换的CAC积分之间的关联。
在研究的1071名参与者中,在校正CHD风险因素(年龄、男性、总胆固醇和高密度脂蛋白胆固醇、糖尿病、吸烟史、体重指数和收缩压)、血清肌酐以及他汀类药物和高血压药物使用情况后,同型半胱氨酸与CAC量相关(P = 0.01)。当根据10年CHD发病风险分层评估这种关联时,在CHD 10年发病风险为中等(6%-20%)的参与者中,同型半胱氨酸与CAC量显著相关(P = 0.003),独立于其他风险因素,但在低风险或高风险参与者中则不然。
血浆同型半胱氨酸与CAC量相关,独立于CHD风险因素。当按10年CHD发病风险类别进行研究时,这种关联在中等风险参与者中显著,但在低风险或高风险参与者中不显著。血浆同型半胱氨酸水平可能作为此类个体CHD风险的标志物具有临床应用价值。